Beta-lactam derivatives inhibit QPCTL for cancer and Alzheimer's
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases associated with aberrant glutaminyl-peptide cyclotransferase-like protein (QPCTL) activity, such as certain cancers and Alzheimer's disease, lack effective inhibitors to modulate QPCTL activity.
Innovation Solution
Development of beta-lactam derivatives represented by Formula (I) or its pharmaceutically acceptable salts/solvates, which act as inhibitors of glutaminyl-peptide cyclotransferase-like protein (QPCTL).
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for diseases associated with aberrant QPCTL activity, then existing therapeutic options are available, but effective inhibition of QPCTL activity cannot be achieved
Solution Approach 1:
The invention segments the broad category of enzyme inhibitors into specific beta-lactam derivative compounds tailored for QPCTL inhibition. By developing a series of structurally related but distinct beta-lactam compounds (Formula I and Formula II), the patent creates specialized inhibitors that specifically target QPCTL, thereby achieving effective inhibition where previous general treatments failed.
Solution Approach 2:
The invention applies parameter changes by systematically varying the chemical structure parameters of beta-lactam derivatives (different R groups, substituents, and molecular configurations) to optimize QPCTL inhibition. This structural parameter optimization enables the compounds to effectively bind and inhibit QPCTL activity, transforming the therapeutic landscape for diseases involving aberrant QPCTL activity.
2Ease of manufacture
If no specific QPCTL inhibitors exist, then current treatments cannot target the underlying mechanism, but developing new compounds increases treatment complexity
Solution Approach 1:
The beta-lactam derivative compounds disclosed serve multiple functions: they act as QPCTL inhibitors, can be formulated into various pharmaceutical compositions, and are applicable to multiple diseases associated with aberrant QPCTL activity (cancers, Alzheimer's disease, etc.). This multi-functionality simplifies the overall therapeutic approach by providing a single class of compounds that addresses multiple therapeutic needs.
Solution Approach 2:
The beta-lactam derivatives act as intermediary molecules that mediate between the administered drug and the QPCTL enzyme. These compounds specifically bind to QPCTL, inhibiting its activity and thereby mediating the therapeutic effect against diseases driven by aberrant QPCTL activity, such as certain cancers and Alzheimer's disease.
3Reliability
If QPCTL activity is not inhibited, then disease progression continues, but without effective inhibitors therapeutic intervention is limited
Solution Approach 1:
The beta-lactam derivative compounds exert preliminary anti-action by preemptively inhibiting QPCTL activity before it can drive disease progression. By blocking the enzyme's function in advance, these compounds prevent the formation of pyroglutamyl groups that would otherwise promote pathological processes in cancers and neurodegenerative diseases, thereby providing reliable disease treatment efficacy.
Solution Approach 2:
The invention utilizes parameter changes in the chemical structure of beta-lactam derivatives to achieve effective QPCTL inhibition. By optimizing molecular parameters such as substituent groups, ring structures, and stereochemistry, the patent develops compounds with enhanced binding affinity and inhibitory potency, thereby improving disease treatment efficacy while expanding available therapeutic options.
Data Source
AI summary
The disclosure provides for compounds and methods for modulating or inhibiting glutaminyl-peptide cyclotransferase-like protein (QPCTL). In one aspect, described herein are compounds of Formulas (I), (Ia), (Ib), (Iaa), (Iab), (Iba), (Ibb), (II), (IIa), (IIb), (IIaa) (IIab), (IIba), and (IIbb), stereoisomer thereof, or salts or solvates thereof. Further provided herein are methods of treating a disease or a condition comprising administering a compound of Formula (I), (Ia), (Ib), (Iaa), (Iab), (Iba), (Ibb), (II), (IIa), (IIb), (IIaa) (IIab), (IIba), or (IIbb), a stereoisomer thereof, or a salt or solvate thereof.